DK1409506T3 - Fremgangsmåder og sammensætninger til RNAi-formidlet inhibering af genekspression i pattedyr - Google Patents

Fremgangsmåder og sammensætninger til RNAi-formidlet inhibering af genekspression i pattedyr

Info

Publication number
DK1409506T3
DK1409506T3 DK02761123.5T DK02761123T DK1409506T3 DK 1409506 T3 DK1409506 T3 DK 1409506T3 DK 02761123 T DK02761123 T DK 02761123T DK 1409506 T3 DK1409506 T3 DK 1409506T3
Authority
DK
Denmark
Prior art keywords
methods
compositions
mammals
rnai
gene expression
Prior art date
Application number
DK02761123.5T
Other languages
Danish (da)
English (en)
Inventor
Mark Kay
Anton Mccaffrey
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK1409506T3 publication Critical patent/DK1409506T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
DK02761123.5T 2001-07-23 2002-07-19 Fremgangsmåder og sammensætninger til RNAi-formidlet inhibering af genekspression i pattedyr DK1409506T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30741101P 2001-07-23 2001-07-23
US36066402P 2002-02-27 2002-02-27
PCT/US2002/022869 WO2003010180A1 (en) 2001-07-23 2002-07-19 Methods and compositions for rnai mediated inhibition of gene expression in mammals

Publications (1)

Publication Number Publication Date
DK1409506T3 true DK1409506T3 (da) 2012-08-06

Family

ID=26975733

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02761123.5T DK1409506T3 (da) 2001-07-23 2002-07-19 Fremgangsmåder og sammensætninger til RNAi-formidlet inhibering af genekspression i pattedyr
DK10178509.5T DK2280070T3 (en) 2001-07-23 2002-07-19 Methods and compositions for use in RNAi-mediated inhibition of gene expression in mammals

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10178509.5T DK2280070T3 (en) 2001-07-23 2002-07-19 Methods and compositions for use in RNAi-mediated inhibition of gene expression in mammals

Country Status (9)

Country Link
US (3) US20030153519A1 (enExample)
EP (2) EP1409506B1 (enExample)
JP (4) JP2005508306A (enExample)
AT (1) ATE556720T1 (enExample)
CA (2) CA2936534C (enExample)
DK (2) DK1409506T3 (enExample)
ES (2) ES2386775T3 (enExample)
PT (1) PT2280070E (enExample)
WO (1) WO2003010180A1 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143204A1 (en) * 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
US20050222075A1 (en) * 1998-09-14 2005-10-06 Hans Herweijer Process for delivering nucleic acids to cardiac tissue
JP2002542263A (ja) * 1999-04-21 2002-12-10 ワイス ポリヌクレオチド配列の機能を阻害するための方法および組成物
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
CA2403397A1 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
US10590418B2 (en) * 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
PT2280070E (pt) 2001-07-23 2015-10-29 Univ Leland Stanford Junior Métodos e composições para inibição mediada por iarn da expressão génica em mamíferos
US7101995B2 (en) * 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
JP4353798B2 (ja) 2001-09-25 2009-10-28 オンコセラピー・サイエンス株式会社 肝細胞癌に関連する遺伝子およびタンパク質
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
ATE529512T1 (de) 2002-02-01 2011-11-15 Life Technologies Corp Doppelsträngige oligonukleotide
AU2003224087B2 (en) * 2002-04-18 2009-03-05 Opko Pharmaceuticals, Llc. Means and methods for the specific inhibition of genes in cells and tissue of the CNS and/or eye
US20030228691A1 (en) * 2002-05-17 2003-12-11 Lewis David L. Processes for inhibiting gene expression using polynucleotides
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP1532248B1 (en) * 2002-07-26 2009-04-01 Novartis Vaccines and Diagnostics, Inc. Modified small interfering rna molecules and methods of use
US20050042646A1 (en) 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
EP2112229A3 (en) 2002-11-25 2009-12-02 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US7781415B2 (en) * 2003-02-07 2010-08-24 Roche Madison Inc. Process for delivering sirna to cardiac muscle tissue
SI1897548T2 (sl) * 2003-02-28 2024-09-30 The Johns Hopkins University Regulacija celic T
WO2004076623A2 (en) * 2003-02-28 2004-09-10 Oncotherapy Science, Inc. Rna-interference for znfn3a1-gene as a method for inhibiting cancer cell growth
US7750144B2 (en) * 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
WO2005007853A2 (en) * 2003-06-06 2005-01-27 Senesco Technologies, Inc. Inhibition of apoptosis-specific elf-5a (“eif-5a1”) with antisense oligonucleotides and sirnas as anti-inflammatory therapeutics
WO2005026322A2 (en) * 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
TWI350373B (en) 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
JP2007527240A (ja) * 2004-03-01 2007-09-27 マサチューセッツ インスティテュート オブ テクノロジー アレルギー性鼻炎および喘息のためのＲＮＡｉベースの治療
US20050233994A1 (en) * 2004-04-16 2005-10-20 Ajamete Kaykas Methods and vectors for expressing siRNA
WO2005118640A2 (en) 2004-04-20 2005-12-15 University Of Utah Research Foundation A h+-gated ion channel
EP1775936A4 (en) * 2004-06-22 2016-05-11 Nikon Corp PICTURE PROCESSING DEVICE CONFIRMING TEXTURE, PICTURE PROCESSING PROGRAM, ELECTRONIC CAMERA AND PICTURE PROCESSING METHOD
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
CA2576576A1 (en) * 2004-08-11 2006-02-16 Receptor Biologix, Inc. Gastrin-specific interfering rna
EP1793835A4 (en) * 2004-09-10 2010-12-01 Somagenics Inc SMALL INTERFERING RNA EFFECTIVELY INHIBITING VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF
WO2006039656A2 (en) * 2004-10-01 2006-04-13 Novartis Vaccines And Diagnostics Inc. Modified small interfering rna molecules and methods of use
US8765704B1 (en) 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
EP1817583A4 (en) 2004-12-02 2009-06-03 Univ Massachusetts GENES AND POLYPEPTIDES ASSOCIATED WITH TRANSPORT OF GLUCOSE AND METHODS OF USE THEREOF
US20060142228A1 (en) * 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
CN101124339A (zh) * 2004-12-30 2008-02-13 托德·M·豪泽 使用自我保护寡核苷酸调节基因表达的组合物和方法
AU2005326371A1 (en) * 2005-01-28 2006-08-03 Kyowa Hakko Kirin Co., Ltd. Composition for inhibiting expression of target gene
US7939254B2 (en) 2005-02-28 2011-05-10 Oncotherapy Science, Inc. Breast cancer related gene ZNFN3A1
EP1714970A1 (en) * 2005-04-22 2006-10-25 Universität des Saarlandes Use of inhibitors of RNAse A-family enzymes for stabilizing oligonucleotides having RNA interfering activity
TW200741009A (en) 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
US7919583B2 (en) * 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
US7723314B1 (en) 2005-10-28 2010-05-25 Transderm, Inc. Methods and compositions for treating pachyonychia congenita
EP1970078A4 (en) 2006-01-11 2010-11-17 Kyowa Hakko Kirin Co Ltd COMPOSITION INHIBITING THE EXPRESSION OF A TARGET GENE OF THE OCULAR GLOBE AND REMEDY FOR OCULAR GLOBE DISEASE
EP1979485A2 (en) 2006-01-31 2008-10-15 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
WO2007097125A1 (ja) * 2006-02-27 2007-08-30 Nikon Corporation 画像の質感を補正する画像処理装置、画像処理プログラム、画像処理方法、および電子カメラ
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
WO2007140599A1 (en) 2006-06-05 2007-12-13 Cancer Care Ontario Assessment of risk for colorectal cancer
DK2029746T3 (da) * 2006-06-12 2012-10-08 Exegenics Inc D B A Opko Health Inc Sammensætninger og fremgangsmåder til siRNA-hæmning af angiogenese
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
CA2679954A1 (en) 2007-03-05 2008-09-12 Cancer Care Ontario Assessment of risk for colorectal cancer
JP5272134B2 (ja) 2007-06-14 2013-08-28 オンコセラピー・サイエンス株式会社 Ｓｍｙｄ３によるｖｅｇｆｒ１のメチル化調整因子を同定する方法
EP2170395A1 (en) * 2007-07-02 2010-04-07 Wyeth LLC Modulators of axl for use in treating bone disorders
WO2010008562A2 (en) 2008-07-16 2010-01-21 Recombinetics Methods and materials for producing transgenic animals
ES2561812T3 (es) 2008-08-01 2016-03-01 Kyowa Hakko Kirin Co., Ltd. Composición para inhibir la expresión de un gen diana
MX2011005851A (es) 2008-12-04 2011-07-29 Opko Opthalmics Llc Composiciones y metodos para la inhibicion selectiva de isoformas vegf proangiogenicas.
JP5875976B2 (ja) 2009-06-01 2016-03-02 ヘイロー−バイオ アールエヌエーアイ セラピューティクス， インコーポレイテッド 多価ｒｎａ干渉のためのポリヌクレオチド、組成物およびそれらの使用方法
EP2454371B1 (en) 2009-07-13 2021-01-20 Somagenics, Inc. Chemical modification of small hairpin rnas for inhibition of gene expression
EP2666856A4 (en) 2011-01-19 2015-01-14 Kyowa Hakko Kirin Co Ltd COMPOSITION TO INHIBIT TARGET EXPRESSION
WO2012151517A1 (en) 2011-05-05 2012-11-08 Coordinated Program Development, Llc Cochleate compositions and methods of making and using same
US9913907B2 (en) 2012-07-16 2018-03-13 Kyowa Hakko Kirin Co., Ltd. RNAi pharmaceutical composition for suppressing expression of KRAS gene
JP6431480B2 (ja) 2012-08-31 2018-11-28 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病の治療および診断のためのビオチン複合体
CN104342453A (zh) 2013-08-06 2015-02-11 深圳先进技术研究院 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
US9545417B2 (en) 2014-05-01 2017-01-17 The Johns Hopkins University Methods of inhibiting cancer stem cells with HMGA1 inhibitors
EP3160479A4 (en) * 2014-06-30 2018-07-04 Academia Sinica Antagonists for interleukin-17 receptor b (il-17rb) and its ligand il-17b for cancer therapy
WO2016022947A1 (en) 2014-08-07 2016-02-11 The Johns Hopkins University Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases
US10265372B2 (en) 2014-08-12 2019-04-23 The Regents Of The University Of California Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues
US11219670B2 (en) 2014-09-05 2022-01-11 The Johns Hopkins University Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
AU2016265948B2 (en) 2015-05-18 2018-12-06 Alkahest, Inc. Methods and compositions for treating aging-associated impairments
AU2016312530A1 (en) 2015-08-24 2018-03-01 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
SG10201912574WA (en) 2016-09-28 2020-02-27 Blade Therapeutics Inc Calpain modulators and therapeutic uses thereof
EP4225904A4 (en) 2020-10-09 2025-10-08 Univ Massachusetts TARGETING NRIP1 TO ALLEVIATE METABOLIC DISEASE

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
US6344321B1 (en) 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
CA2038839A1 (en) * 1991-03-22 1992-09-23 Jiang J. Liu Method for detection of viral rna
ES2040615B1 (es) * 1991-05-27 1994-05-16 Nebrda Fernando Javi Bartolome Procedimiento para el aislamiento y clonaje de cdnas derivados del virus c de la hepatitis.
US6030954A (en) * 1991-09-05 2000-02-29 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
AU6230594A (en) * 1993-02-01 1994-08-29 University Of Iowa Research Foundation, The Quartenary amine surfactants and methods of using same in isolation of rna
US5985847A (en) 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
US5712384A (en) * 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
EP0759979A4 (en) * 1994-05-10 1999-10-20 Gen Hospital Corp THE ANTISENSE INHIBITION OF HEPATITIS C VIRUS
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US5981279A (en) * 1995-11-09 1999-11-09 Allegheny University Of The Health Sciences Compositions and methods to regulate calmodulin gene expression, and uses thereof for influencing cell growth and differentiation
JP4033502B2 (ja) 1996-02-08 2008-01-16 アンジェスＭｇ株式会社 リボザイム、リポソーム製剤及びその用途
EP0932698A1 (en) * 1996-03-26 1999-08-04 Lynx Therapeutics, Inc. Oligonucleotide treatments and compositions for human melanoma
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
ES2187972T3 (es) 1997-04-04 2003-06-16 Max Planck Gesellschaft Metodos para la modulacion del crecimiento de arterias colaterales y/u otras arterias a partir de conexiones arteriolares preexistentes.
US5948902A (en) 1997-11-20 1999-09-07 South Alabama Medical Science Foundation Antisense oligonucleotides to human serine/threonine protein phosphatase genes
US5957978A (en) 1997-12-22 1999-09-28 Hansa Medical Products, Inc. Valved fenestrated tracheotomy tube
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
PL343064A1 (en) 1998-03-20 2001-07-30 Benitec Australia Ltd Control of gene expression
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
JP2002542263A (ja) * 1999-04-21 2002-12-10 ワイス ポリヌクレオチド配列の機能を阻害するための方法および組成物
GB9925459D0 (en) * 1999-10-27 1999-12-29 Plant Bioscience Ltd Gene silencing
WO2001032223A1 (en) 1999-11-05 2001-05-10 Mirus Corporation Intravascular delivery of nucleic acid
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
CA2403397A1 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
GB2377221B (en) 2000-03-17 2004-08-18 Benitec Australia Ltd Genetic silencing
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US20020132788A1 (en) * 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
DK1407044T4 (en) * 2000-12-01 2017-12-04 Max-Planck-Gesellschaft Zur Förderung Der Wss E V RNA interference mediating small RNA molecules
DE10100588A1 (de) 2001-01-09 2002-07-18 Ribopharma Ag Verfahren zur Hemmung der Expression eines Zielgens
EP1390472A4 (en) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS
US7000102B2 (en) 2001-06-29 2006-02-14 Intel Corporation Platform and method for supporting hibernate operations
CA2921821A1 (en) 2001-07-12 2003-01-23 University Of Massachusetts In vivo production of small interfering rnas that mediate gene silencing
PT2280070E (pt) 2001-07-23 2015-10-29 Univ Leland Stanford Junior Métodos e composições para inibição mediada por iarn da expressão génica em mamíferos
JP2005517427A (ja) 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＣ型肝炎ウイルス（ＨＣＶ）遺伝子発現のＲＮＡ干渉媒介性阻害

Also Published As

Publication number Publication date
US20130312126A1 (en) 2013-11-21
EP2280070B1 (en) 2015-05-20
ATE556720T1 (de) 2012-05-15
JP2011093906A (ja) 2011-05-12
JP6055164B2 (ja) 2016-12-27
HK1065562A1 (en) 2005-02-25
ES2386775T3 (es) 2012-08-30
PT2280070E (pt) 2015-10-29
JP6247355B2 (ja) 2017-12-13
JP2005508306A (ja) 2005-03-31
EP2280070A1 (en) 2011-02-02
EP1409506B1 (en) 2012-05-09
ES2546829T3 (es) 2015-09-29
JP2015044809A (ja) 2015-03-12
US20200246370A1 (en) 2020-08-06
EP1409506A1 (en) 2004-04-21
CA2936534A1 (en) 2003-02-06
DK2280070T3 (en) 2015-08-24
CA2454183C (en) 2016-09-06
WO2003010180A1 (en) 2003-02-06
CA2936534C (en) 2021-01-26
US20030153519A1 (en) 2003-08-14
CA2454183A1 (en) 2003-02-06
EP1409506A4 (en) 2004-11-17
JP2017008084A (ja) 2017-01-12
US10517887B2 (en) 2019-12-31

Similar Documents

Publication Publication Date Title
DK1409506T3 (da) Fremgangsmåder og sammensætninger til RNAi-formidlet inhibering af genekspression i pattedyr
WO2020198509A3 (en) Modified oligonucleotides with increased stability
MX2022009280A (es) Vacunas de arn contra el coronavirus.
DE60113805D1 (de) Intratumorale verabreichung nackter il-12 codierender nukleinsäuremoleküle
CY1110259T1 (el) Ανοσορυθμιστης
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
NZ553828A (en) Method of treating an inflammatory disease by double stranded ribonucleic acid by inhibiting TNF-alpha
ATE386127T1 (de) Verbesserung der immunantwort als anwendung in impfstoff und gentherapie
TW200505480A (en) High concentration antibody and protein formulations
BRPI0510475B8 (pt) adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
EA200800838A1 (ru) Модуляция иммуностимулирующих свойств короткой интерферирующей рибонуклеиновой кислоты (siphk) с помощью модификации нуклеотидов
DK1301201T3 (da) Behandling af glycogenosis type II
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
DK2219031T3 (da) Anvendelse af leptin til behandling af human lipoatrofi og fremgangsmåde til bestemmelse af prædisposition for behandlinngen
MX2022014161A (es) Vacunas contra sars-cov-2.
ATE527378T1 (de) Antisense-modulation von p38-mitogen-aktivierter proteinkinase-expression
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
BRPI0409865A (pt) injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia
CY1108552T1 (el) Θεραπευτικη αντιμετωπιση της μη αλκοολικης στεατοηπατιτιδας (nash)
DE60144525D1 (de) Des protein (igfbp)-2-oligodeoxynukleotide zur behandlung von prostatakrebs
WO2021131944A8 (ja) 癌遺伝子治療薬
DK1814907T3 (da) Sæt af dele til designet til implementering af en antitumoral eller antiviral behandling hos et pattedyr
ATE428783T1 (de) Expressionssystem für sirna
MX2023005154A (es) Nanopartículas codificadas de adn y método de uso de las mismas como una vacuna contra la enfermedad corona virus (covid-19).
ITMI20030860A1 (it) Metodo per l'inibizione selettiva del gene n-myc